<p>ImmunoPrecise Antibodies（纳斯达克：IPA - 获取免费报告）可能会在 2025 年 9 月 15 日星期一市场开盘前公布其 2026 年第一季度的业绩。分析师预计该公司将宣布每股收益为（$0.04），季度收入为 590 万美元。投资者可以访问该公司即将发布的 2026 年第一季度财报页面，以获取关于定于 2025 年 9 月 15 日东部时间上午 10:30 的电话会议的最新详情。</p>
<ul>
<li>3 只个人护理股票，似乎是良好的收益投资机会</li>
</ul>
<p>ImmunoPrecise Antibodies（纳斯达克：IPA - 获取免费报告）上一次公布其财报是在 7 月 29 日星期二。该公司报告季度每股收益（EPS）为（$0.04），低于市场共识预期的（$0.02）$0.02。该季度的收入为 506 万美元，而市场共识预期为 789 万美元。ImmunoPrecise Antibodies 的净利润率为-122.10%，股本回报率为-40.62%。分析师平均预计 ImmunoPrecise Antibodies 在当前财年将发布$0 的每股收益，并在下一个财年也将发布$0 的每股收益。</p>
<h2>ImmunoPrecise Antibodies 股价上涨 8.5%</h2>
<p>IPA 周一开盘价为$2.10。该公司的流动比率为 2.08，速动比率为 1.85，债务与股本比率为 0.49。该公司的市值为 9668 万美元，市盈率为-3.08，贝塔值为 0.53。ImmunoPrecise Antibodies 的 12 个月最低价为$0.27，最高价为$3.25。该股票的 50 日移动平均价格为$1.98，200 日移动平均价格为$1.03。</p>
<h2>华尔街分析师观点</h2>
<ul>
<li>MarketBeat 周报 – 07/31 - 08/04</li>
</ul>
<p>另外，华尔街 Zen 在 8 月 2 日星期六的报告中将 ImmunoPrecise Antibodies 的股票评级从 “卖出” 上调至 “持有”。根据 MarketBeat 的数据显示，有两位投资分析师对该股票给予了买入评级。目前，ImmunoPrecise Antibodies 的平均评级为 “买入”，平均目标价为$4.00。</p>
<p><strong>查看我们对 IPA 的最新股票分析</strong></p>
<h2>ImmunoPrecise Antibodies 的机构交易</h2>
<ul>
<li>这款香水热潮赢家似乎要创下新高</li>
</ul>
<p>一家对冲基金最近增加了对 ImmunoPrecise Antibodies 股票的持股。根据该公司最近向证券交易委员会（SEC）提交的 13F 表格，XTX Topco Ltd 在第二季度将其在 ImmunoPrecise Antibodies Ltd.（纳斯达克：IPA - 免费报告）的持股增加了 394.4%。该基金在此期间购买了 72897 股后，持有 91382 股该公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，XTX Topco Ltd 持有的 ImmunoPrecise Antibodies 的股份约占 0.20%，价值 97000 美元。对冲基金和其他机构投资者持有该公司 6.70% 的股份。</p>
<h2>ImmunoPrecise Antibodies 公司简介</h2>
<p>（获取免费报告）</p>
<p>ImmunoPrecise Antibodies Ltd.及其子公司在加拿大及国际上作为生物治疗研究和技术公司运营。它提供用于复杂蛋白质类别的 NonaVac DNA，包括 GPCRs 和离子通道；以及用于生成抗类抗体的阳性单克隆抗体 Rapid Prime，并生产针对构象表位的单克隆抗体。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 ImmunoPrecise Antibodies</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>联合太平洋：为美国工业复兴铺轨</li>
<li>什么是成长股及其投资</li>
<li>TransDigm 的优势：从备件到高额利润</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Spire Global：小卫星，大买入评级和上涨空间</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 ImmunoPrecise Antibodies 吗？</h2>
<p>在你考虑 ImmunoPrecise Antibodies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 ImmunoPrecise Antibodies 并不在名单上。</p>
<p>虽然 ImmunoPrecise Antibodies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>ImmunoPrecise Antibodies（纳斯达克代码：IPA）将于 9 月 15 日发布 2026 年第一季度财报，分析师预测每股亏损 0.04 美元，收入为 590 万美元。该公司上个季度报告的每股亏损为 0.04 美元，收入为 506 万美元。目前，ImmunoPrecise 的市值为 9668 万美元，市盈率为-3.08。分析师维持 “买入” 评级，平均目标价为 4.00 美元。机构投资者持有该公司 6.70% 的股份</p>

<p>ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Monday, September 15th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $5.90 million for the quarter. Investors may visit the the company's upcoming Q1 2026 earningresults page for the latest details on the call scheduled for Monday, September 15, 2025 at 10:30 AM ET.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies（纳斯达克：IPA - 获取免费报告）可能会在 2025 年 9 月 15 日星期一市场开盘前公布其 2026 年第一季度的业绩。分析师预计该公司将宣布每股收益为（$0.04），季度收入为 590 万美元。投资者可以访问该公司即将发布的 2026 年第一季度财报页面，以获取关于定于 2025 年 9 月 15 日东部时间上午 10:30 的电话会议的最新详情。</p>
</div><ul>
<li>3 personal care stocks that smell like good earnings plays</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只个人护理股票，似乎是良好的收益投资机会</li>
</ul>
</div><p>ImmunoPrecise Antibodies (NASDAQ:IPA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative net margin of 122.10% and a negative return on equity of 40.62%. On average, analysts expect ImmunoPrecise Antibodies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies（纳斯达克：IPA - 获取免费报告）上一次公布其财报是在 7 月 29 日星期二。该公司报告季度每股收益（EPS）为（$0.04），低于市场共识预期的（$0.02）$0.02。该季度的收入为 506 万美元，而市场共识预期为 789 万美元。ImmunoPrecise Antibodies 的净利润率为-122.10%，股本回报率为-40.62%。分析师平均预计 ImmunoPrecise Antibodies 在当前财年将发布$0 的每股收益，并在下一个财年也将发布$0 的每股收益。</p>
</div><h2>ImmunoPrecise Antibodies Trading Up 8.5%</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 股价上涨 8.5%</h2>
</div><p>IPA opened at $2.10 on Monday. The company has a current ratio of 2.08, a quick ratio of 1.85 and a debt-to-equity ratio of 0.49. The firm has a market cap of $96.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.53. ImmunoPrecise Antibodies has a 12 month low of $0.27 and a 12 month high of $3.25. The stock has a fifty day moving average price of $1.98 and a 200-day moving average price of $1.03.</p>
<div class="lb-trans"><p>IPA 周一开盘价为$2.10。该公司的流动比率为 2.08，速动比率为 1.85，债务与股本比率为 0.49。该公司的市值为 9668 万美元，市盈率为-3.08，贝塔值为 0.53。ImmunoPrecise Antibodies 的 12 个月最低价为$0.27，最高价为$3.25。该股票的 50 日移动平均价格为$1.98，200 日移动平均价格为$1.03。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><ul>
<li>MarketBeat Week in Review – 07/31 - 08/04</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 07/31 - 08/04</li>
</ul>
</div><p>Separately, Wall Street Zen upgraded shares of ImmunoPrecise Antibodies from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 2nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, ImmunoPrecise Antibodies currently has an average rating of &#34;Buy&#34; and an average target price of $4.00.</p>
<div class="lb-trans"><p>另外，华尔街 Zen 在 8 月 2 日星期六的报告中将 ImmunoPrecise Antibodies 的股票评级从 “卖出” 上调至 “持有”。根据 MarketBeat 的数据显示，有两位投资分析师对该股票给予了买入评级。目前，ImmunoPrecise Antibodies 的平均评级为 “买入”，平均目标价为$4.00。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on IPA</strong></p>
<div class="lb-trans"><p><strong>查看我们对 IPA 的最新股票分析</strong></p>
</div><h2>Institutional Trading of ImmunoPrecise Antibodies</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 的机构交易</h2>
</div><ul>
<li>Smells Like New Highs for This Fragrance Boom Winner</li>
</ul>
<div class="lb-trans"><ul>
<li>这款香水热潮赢家似乎要创下新高</li>
</ul>
</div><p>A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. XTX Topco Ltd increased its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA - Free Report) by 394.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,382 shares of the company's stock after purchasing an additional 72,897 shares during the period. XTX Topco Ltd owned approximately 0.20% of ImmunoPrecise Antibodies worth $97,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.70% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近增加了对 ImmunoPrecise Antibodies 股票的持股。根据该公司最近向证券交易委员会（SEC）提交的 13F 表格，XTX Topco Ltd 在第二季度将其在 ImmunoPrecise Antibodies Ltd.（纳斯达克：IPA - 免费报告）的持股增加了 394.4%。该基金在此期间购买了 72897 股后，持有 91382 股该公司的股票。根据其最近向证券交易委员会（SEC）提交的文件，XTX Topco Ltd 持有的 ImmunoPrecise Antibodies 的股份约占 0.20%，价值 97000 美元。对冲基金和其他机构投资者持有该公司 6.70% 的股份。</p>
</div><h2>ImmunoPrecise Antibodies Company Profile</h2>
<div class="lb-trans"><h2>ImmunoPrecise Antibodies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.</p>
<div class="lb-trans"><p>ImmunoPrecise Antibodies Ltd.及其子公司在加拿大及国际上作为生物治疗研究和技术公司运营。它提供用于复杂蛋白质类别的 NonaVac DNA，包括 GPCRs 和离子通道；以及用于生成抗类抗体的阳性单克隆抗体 Rapid Prime，并生产针对构象表位的单克隆抗体。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than ImmunoPrecise Antibodies</li>
<li>Stock Splits, Do They Really Impact Investors?</li>
<li>Union Pacific: Laying the Tracks for America's Industrial Renewal</li>
<li>What Are Growth Stocks and Investing in Them</li>
<li>TransDigm’s Edge: From Spare Parts to Sky-High Profits</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Spire Global: Tiny Satellites, Big Buy Ratings and Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 ImmunoPrecise Antibodies</li>
<li>股票拆分，真的会影响投资者吗？</li>
<li>联合太平洋：为美国工业复兴铺轨</li>
<li>什么是成长股及其投资</li>
<li>TransDigm 的优势：从备件到高额利润</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Spire Global：小卫星，大买入评级和上涨空间</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVBB" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=IPA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in ImmunoPrecise Antibodies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 ImmunoPrecise Antibodies 吗？</h2>
</div><p>Before you consider ImmunoPrecise Antibodies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 ImmunoPrecise Antibodies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunoPrecise Antibodies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 ImmunoPrecise Antibodies 并不在名单上。</p>
</div><p>While ImmunoPrecise Antibodies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 ImmunoPrecise Antibodies 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

ImmunoPrecise Antibodies (IPA) 将在周一公布季度财报